Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 8/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | CPB1 | P15086 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14551478 | 0.86 | CPB2 (0.39) | CPB2KDM4ECPB1MEN1KMT2A | |
| SCHEMBL14481389 | 0.81 | CPB2 (0.44) | CPB2CPB1 | |
| SCHEMBL14551489 | 0.78 | MEN1 (0.43) | SMN1; SMN2TBXAS1KDM4EMEN1KMT2A | |
| SCHEMBL14790043 | 0.76 | CPB2 (0.38) | CPB2CPB1 | |
| SCHEMBL8455536 | 0.75 | ALDH1A1 (0.49) | TBXAS1MEN1KMT2AALDH1A1 | |
| SCHEMBL10137877 | 0.73 | CPB2 (0.52) | CPB2KDM4ECPB1ALDH1A1 | |
| SCHEMBL1025097 | 0.71 | RAB9A (0.52) | SMN1; SMN2KDM4EALDH1A1RAB9A | |
| SCHEMBL14789440 | 0.70 | CPB2 (0.43) | CPB2CPB1 | |
| SCHEMBL20596005 | 0.69 | LMNA (0.45) | SMN1; SMN2KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL6369922 | 0.69 | CPB2 (0.39) | CPB2SMN1; SMN2TBXAS1CPB1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9662310-B2 | Cyclopropanecarboxylic acid derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-05-30 | — | — | US | disclosed |
| US-9662310-B2 | Cyclopropanecarboxylic acid derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-05-30 | — | — | US | disclosed |
| EP-2548872-B1 | CYCLOPROPANECARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2016-09-28 | — | — | EP | disclosed |
| US-20150216847-A1 | CYCLOPROPANECARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-08-06 | — | — | US | disclosed |
| US-20150216847-A1 | CYCLOPROPANECARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-08-06 | — | — | US | disclosed |
| US-8946443-B2 | Cyclopropanecarboxylic acid derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-02-03 | — | — | US | disclosed |
| US-8946443-B2 | Cyclopropanecarboxylic acid derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-02-03 | — | — | US | disclosed |
| EP-2548872-A1 | CYCLOPROPANECARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-01-23 | — | — | EP | disclosed |
| US-20130012532-A1 | CYCLOPROPANECARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-01-10 | — | — | US | disclosed |
| US-20130012532-A1 | CYCLOPROPANECARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012532-A1 | CYCLOPROPANECARBOXYLIC ACID DERIVATIVE | TFPI, TFPI2, TAF11 | CPB2 13/4885SMN1; SMN2 3906/4885TBXAS1 12/4885 |
| US-20150216847-A1 | CYCLOPROPANECARBOXYLIC ACID DERIVATIVE | TFPI, TFPI2, TAF11 | CPB2 13/4885SMN1; SMN2 3906/4885TBXAS1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.